search
Back to results

Monitoring of patIents With Microdialysis Following Pancreaticoduodenectomy (MINIMUM)

Primary Purpose

Pancreatic Cancer, Pancreatic Neoplasms, Biliary Tract Cancer

Status
Active
Phase
Not Applicable
Locations
Norway
Study Type
Interventional
Intervention
Surgical og radiological intervention, antibiotics
Sponsored by
Oslo University Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Pancreatic Cancer focused on measuring Pancreaticoduodenectomy, Pancreatectomy, Anastomosis, Surgical

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patients must be scheduled for a pancreaticoduodenectomy
  • Subject must be ≥ 18 years
  • Able to give written signed informed consent
  • Investigator's assessment that the patient is able to understand, comply and follow the instructions needed to successfully participate in this trial

Exclusion Criteria:

  • Allergic to Voluven® (Fresenius Kabi AS, Halden, Norway) and contrast given during CT scan
  • Another study interfering with current study
  • Pregnant

Sites / Locations

  • Oslo University Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

No Intervention

Arm Label

Patient with microdialysis

Patient without microdialysis

Arm Description

Intervention group - Patients will receive an intraperitoneal microdialysis catheter and will be monitored consecutively by microdialysis. The surgeon is familiar with the current microdialysis results at any time during the study period. The surgeon may intervene based on traditional symptoms and signs plus predetermined values of the microdialysis results.

The control group - The patients will not receive a microdialysis catheter. The patients are monitored according to current standards of care and the surgeon may intervene based only on traditional symptoms and signs.

Outcomes

Primary Outcome Measures

Total hospital stay
Number of days from end of surgery to hospital discharge (at any hospital)

Secondary Outcome Measures

Length of stay at the primary hospital
Length of stay at the primary hospital and ICU. Number of days from initial operation to primary hospital discharge.
Concentration of Lactate (mM), Pyruvate (microM), Glycerol (microM), Glucose (mM) in microdialysate
Concentration of Lactate, Pyruvate, Glycerol, Glucose in microdialysate in relation to patients with or without anastomosis leakage
Concentration of inflammatory markers in microdialysate
Concentration of inflammatory markers in microdialysate in relation to patients with or without anastomosis leakage
Concentration of inflammatory markers in serum
Concentration of inflammatory markers in serum in relation to patients with or without anastomosis leakage
Patient-reported quality of life questionnaire - total score assessed by the Abdominal surgery Impact scale by summing subscores
Total score - Abdominal surgery Impact scale. The summative scores for the scale range from 18 to 126, with higher scores indicating better quality of life
Patient-reported quality of life questionnaire - subgroup score Physical limitations assessed by the Abdominal surgery Impact scale
Subgroup score Physical limitations - Abdominal surgery Impact scale. The summative scores for the scale range from 3 to 18, with higher scores indicating better physical ability
Patient-reported quality of life questionnaire - subgroup score Functional impairment assessed by the Abdominal surgery Impact scale
Subgroup score Functional impairment - Abdominal surgery Impact scale. The summative scores for the scale range from 3 to 18, with higher scores indicating better functional ability
Patient-reported quality of life questionnaire - subgroup score Pain assessed by the Abdominal surgery Impact scale
Subgroup score Pain - Abdominal surgery Impact scale. The summative scores for the scale range from 3 to 18, with higher scores indicating more pain
Patient-reported quality of life questionnaire - subgroup score Visceral Function assessed by the Abdominal surgery Impact scale
Subgroup score Visceral Function - Abdominal surgery Impact scale. The summative scores for the scale range from 3 to 18, with higher scores indicating more Visceral dysfunction
Patient-reported quality of life questionnaire - subgroup score Sleep assessed by the Abdominal surgery Impact scale
Subgroup score Sleep - Abdominal surgery Impact scale. The summative scores for the scale range from 3 to 18, with higher scores indicating more sleep dysfunction
Patient-reported quality of life questionnaire - subgroup score Psychological function assessed by the Abdominal surgery Impact scale
Subgroup score Psychological function - Abdominal surgery Impact scale. The summative scores for the scale range from 3 to 18, with higher scores indicating more psychological dysfunction
Patient-reported pain questionnaire - total score assessed by the McGill Pain Questionnaire-2 (SF-MPQ-2)
Total score - McGill Pain Questionnaire-2 (SF-MPQ-2). Subgroup score Psychological function - Abdominal surgery Impact scale. The summative scores ranging from 0 to 45, with higher score indicating more pain
Expenses (Euros) per patient used during total hospital stay
Number of Euros used in patient undergoing pancreaticoduodenectomy With or without microdialysis catheter
Daily assessement of microdialysis catheter malfunction during admission at hospital, at an average of 10 days after surgery
Number of catheter which are not functioning
Risk factors of postoperative pancreatic fistula at discharge from hospital, at an average 10 days after surgery
Numbers of risk factors of postoperative pancreatic fistula in relation to patients with or without anastomosis leakage
Risk factors of postoperative pancreatic fistula at 30 days after surgery
Numbers of risk factors of postoperative pancreatic fistula in relation to patients with or without anastomosis leakage
Risk factors of postoperative pancreatic fistula at 90 days after surgery
Numbers of risk factors of postoperative pancreatic fistula in relation to patients with or without anastomosis leakage

Full Information

First Posted
July 9, 2018
Last Updated
September 28, 2022
Sponsor
Oslo University Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT03631173
Brief Title
Monitoring of patIents With Microdialysis Following Pancreaticoduodenectomy
Acronym
MINIMUM
Official Title
Monitoring of patIents With Microdialysis Following Pancreaticoduodenectomy - a Randomized Controlled Trial. THE MINIMUM STUDY
Study Type
Interventional

2. Study Status

Record Verification Date
September 2022
Overall Recruitment Status
Active, not recruiting
Study Start Date
April 2, 2019 (Actual)
Primary Completion Date
August 1, 2021 (Actual)
Study Completion Date
December 31, 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Oslo University Hospital

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
A pancreaticoduodenectomy is performed in patient with pancreatic cancer. The most common and serious complication is leakage between the intestine and the remnant pancreas after this procedure. It occurs in 20-30%. The result is often prolonged hospital and ICU stay, reoperations and deaths (3-5%). To detect a leakage early before the patient becomes seriously ill, thereby initiating treatment is therefore very important. By inserting a thin microdialysis catheter near the anastomosis between pancreas and intestine before closure of the abdominal wall, the investigators will analyze substances such as lactic acid, pyruvate, glycerol, etc. and if these substances may reveal anastomosis leakage at an early stage. Observational studies have shown that if a leakage occurs, glycerol concentration in the microdialysate will rise significant after few hours, and changes in lactic acid and pyruvate values will change as a sign of inflammation. The investigators want to conduct a randomized study comparing patients undergoing pancreaticoduodenectomy and using microdialysis in half of the included population.
Detailed Description
Anastomotic leakage after pancreaticoduodenectomy is a feared complication with substantial mortality and morbidity. Treatment of a postoperative pancreatic fistula can be difficult and management may range from a simple observation with or without percutaneous drainage, to the urgent need for reoperation and management of abdominal sepsis with organ failure and prolonged intensive care. To diagnose a pancreatic fistula may have a delay of several days. The risk of death and severe morbidity raises considerable from a biochemical pancreatic fistula compared to the most serious form, a grade C. Also, the cost of managing a patient with a fistula is 1.3-6 times more than a patient with no complications after PD. Microdialysis is a promising tool in patients who undergoes pancreaticoduodenectomy for early detection of postoperative pancreatic fistula development. The technique may reveal an fistula before severe symptoms occur and before the complication gives the patient serious and life-threatening symptoms. Earlier intervention of the postoperative pancreatic fistula may lead to better prognosis, less reoperations and interventions and shorter stay at the ICU/hospital. By monitoring intraperitoneal metabolites (glycerol, lactate, pyruvate and glucose) close to the pancreaticojejunostomy, signs of a leakage may be discovered in few hours, thereby make it possible for early intervention and prevent developement of serious progression of morbidity. The investigators want to perform a randomized study where half of the patients will receive a microdialysis catheter implanted close to the pancreaticoduodenal anastomosis before closure of the abdomen. At certain timepoints postoperatively microdialysate will be analyzed for glycerol, lactate, pyruvate and glucose and the data will be used in the decisionmaking of diagnosing a pancreatic anastomosis leakage in addition to standard management. The other half of the patients will not receive a microdialysis catheter and the decisionmaking will only be based on standard management (ie. inflammation markers in blood samples, amylase in drainage fluid).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pancreatic Cancer, Pancreatic Neoplasms, Biliary Tract Cancer, Duodenal Cancer, Pancreatic Fistula
Keywords
Pancreaticoduodenectomy, Pancreatectomy, Anastomosis, Surgical

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
2-armed, multicenter, randomized, open label, parallel-group controlled trial (RCT)
Masking
None (Open Label)
Allocation
Randomized
Enrollment
201 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Patient with microdialysis
Arm Type
Active Comparator
Arm Description
Intervention group - Patients will receive an intraperitoneal microdialysis catheter and will be monitored consecutively by microdialysis. The surgeon is familiar with the current microdialysis results at any time during the study period. The surgeon may intervene based on traditional symptoms and signs plus predetermined values of the microdialysis results.
Arm Title
Patient without microdialysis
Arm Type
No Intervention
Arm Description
The control group - The patients will not receive a microdialysis catheter. The patients are monitored according to current standards of care and the surgeon may intervene based only on traditional symptoms and signs.
Intervention Type
Procedure
Intervention Name(s)
Surgical og radiological intervention, antibiotics
Intervention Description
Intervention might be a new drainage catheter, replacement of old drainage catheter, reoperation, somatostatin- and antibiotic administration.
Primary Outcome Measure Information:
Title
Total hospital stay
Description
Number of days from end of surgery to hospital discharge (at any hospital)
Time Frame
30 days after surgery - postoperative day 30
Secondary Outcome Measure Information:
Title
Length of stay at the primary hospital
Description
Length of stay at the primary hospital and ICU. Number of days from initial operation to primary hospital discharge.
Time Frame
30 days after surgery - postoperative day 30
Title
Concentration of Lactate (mM), Pyruvate (microM), Glycerol (microM), Glucose (mM) in microdialysate
Description
Concentration of Lactate, Pyruvate, Glycerol, Glucose in microdialysate in relation to patients with or without anastomosis leakage
Time Frame
30 days after surgery - postoperative day 30
Title
Concentration of inflammatory markers in microdialysate
Description
Concentration of inflammatory markers in microdialysate in relation to patients with or without anastomosis leakage
Time Frame
30 days after surgery - postoperative day 30
Title
Concentration of inflammatory markers in serum
Description
Concentration of inflammatory markers in serum in relation to patients with or without anastomosis leakage
Time Frame
30 days after surgery - postoperative day 30
Title
Patient-reported quality of life questionnaire - total score assessed by the Abdominal surgery Impact scale by summing subscores
Description
Total score - Abdominal surgery Impact scale. The summative scores for the scale range from 18 to 126, with higher scores indicating better quality of life
Time Frame
From inclusion to 90-days after surgery
Title
Patient-reported quality of life questionnaire - subgroup score Physical limitations assessed by the Abdominal surgery Impact scale
Description
Subgroup score Physical limitations - Abdominal surgery Impact scale. The summative scores for the scale range from 3 to 18, with higher scores indicating better physical ability
Time Frame
From inclusion to 90-days after surgery
Title
Patient-reported quality of life questionnaire - subgroup score Functional impairment assessed by the Abdominal surgery Impact scale
Description
Subgroup score Functional impairment - Abdominal surgery Impact scale. The summative scores for the scale range from 3 to 18, with higher scores indicating better functional ability
Time Frame
From inclusion to 90-days after surgery
Title
Patient-reported quality of life questionnaire - subgroup score Pain assessed by the Abdominal surgery Impact scale
Description
Subgroup score Pain - Abdominal surgery Impact scale. The summative scores for the scale range from 3 to 18, with higher scores indicating more pain
Time Frame
From inclusion to 90-days after surgery
Title
Patient-reported quality of life questionnaire - subgroup score Visceral Function assessed by the Abdominal surgery Impact scale
Description
Subgroup score Visceral Function - Abdominal surgery Impact scale. The summative scores for the scale range from 3 to 18, with higher scores indicating more Visceral dysfunction
Time Frame
From inclusion to 90-days after surgery
Title
Patient-reported quality of life questionnaire - subgroup score Sleep assessed by the Abdominal surgery Impact scale
Description
Subgroup score Sleep - Abdominal surgery Impact scale. The summative scores for the scale range from 3 to 18, with higher scores indicating more sleep dysfunction
Time Frame
From inclusion to 90-days after surgery
Title
Patient-reported quality of life questionnaire - subgroup score Psychological function assessed by the Abdominal surgery Impact scale
Description
Subgroup score Psychological function - Abdominal surgery Impact scale. The summative scores for the scale range from 3 to 18, with higher scores indicating more psychological dysfunction
Time Frame
From inclusion to 90-days after surgery
Title
Patient-reported pain questionnaire - total score assessed by the McGill Pain Questionnaire-2 (SF-MPQ-2)
Description
Total score - McGill Pain Questionnaire-2 (SF-MPQ-2). Subgroup score Psychological function - Abdominal surgery Impact scale. The summative scores ranging from 0 to 45, with higher score indicating more pain
Time Frame
From inclusion to 90-days after surgery
Title
Expenses (Euros) per patient used during total hospital stay
Description
Number of Euros used in patient undergoing pancreaticoduodenectomy With or without microdialysis catheter
Time Frame
30 days after surgery - postoperative day 30
Title
Daily assessement of microdialysis catheter malfunction during admission at hospital, at an average of 10 days after surgery
Description
Number of catheter which are not functioning
Time Frame
From surgery end to discharge from primary hospital, at an average of 10 days after surgery
Title
Risk factors of postoperative pancreatic fistula at discharge from hospital, at an average 10 days after surgery
Description
Numbers of risk factors of postoperative pancreatic fistula in relation to patients with or without anastomosis leakage
Time Frame
From surgery end to discharge from primary hospital at hospital, at an average of 10 days after surgery
Title
Risk factors of postoperative pancreatic fistula at 30 days after surgery
Description
Numbers of risk factors of postoperative pancreatic fistula in relation to patients with or without anastomosis leakage
Time Frame
From surgery end to 30 days after surgery
Title
Risk factors of postoperative pancreatic fistula at 90 days after surgery
Description
Numbers of risk factors of postoperative pancreatic fistula in relation to patients with or without anastomosis leakage
Time Frame
From surgery end to 90 days after surgery
Other Pre-specified Outcome Measures:
Title
Time before postoperative fistula is diagnosed (hours)
Description
Hours from end of surgery to diagnosis of postoperative pancreatic fistula
Time Frame
End of surgery to 30 days postoperative
Title
Total quantity (μg/mg) of vasoactive medications at discharge at an average of 10 days after surgery
Description
Amount of vasoactive medication during surgery and postoperatively until discharge from the hospital where the surgery was performed.
Time Frame
From surgery end to discharge from primary hospital at an average of 10 days after surgery
Title
Number of patients with Pancreatic Fistula
Description
Number of patients with Pancreatic Fistula
Time Frame
30 days after surgery - postoperative day 30
Title
Number of patients with Biliary Fistula
Description
Number of patients with Biliary Fistula
Time Frame
30 days after surgery - postoperative day 30
Title
Number of patients with gastroenteric Fistula
Description
Number of patients with gastroenteric Fistula
Time Frame
30 days after surgery - postoperative day 30
Title
Daily measurements during hospital admission of pancreatic amylase (U/L) and bilirubin (µmol/L ) concentrations in drainage fluid and in serum, at an average og 10 days after surgery
Description
Pancreatic amylase and bilirubin concentrations in drainage fluid and in serum
Time Frame
From surgery end to discharge from primary hospital at an average of 10 days after surgery
Title
Postoperative complications
Description
Number of patients with postoperative complications during total hospital stay
Time Frame
From inclusion to 90-days after surgery
Title
Fluid Balance (ml) during hospital admission at an average of 10 days after surgery
Description
Diuresis and amount of fluid given i.v. during surgery and postoperatively until discharge from the primary hospital
Time Frame
From anesthesia start to discharge from primary hospital at an average of 10 days after surgery
Title
Number of patients discharged to home/self care at an average of 10 days after surgery
Description
Patient's discharge disposition - number of patients Discharged to home/self care
Time Frame
At discharge at an average of 10 days after surgery
Title
Number of patients discharged to home but with home health service at an average of 10 days
Description
Patient's discharge disposition - number of patients Discharged to home but with home health service
Time Frame
At discharge at an average of 10 days after surgery
Title
Number of patients discharged/transferred to nursing home at an average of 10 days
Description
Patient's discharge disposition - number of patients Discharged/transferred to nursing home
Time Frame
At discharge at an average of 10 days after surgery
Title
Number of patients discharged/transferred to an inpatient rehabilitation facility at an average of 10 days
Description
Discharged to an inpatient rehabilitation facility
Time Frame
At discharge at an average of 10 days after surgery
Title
Number of patients expired at an average of 10 days
Description
Patient's discharge disposition - expired
Time Frame
At discharge at an average of 10 days after surgery

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients must be scheduled for a pancreaticoduodenectomy Subject must be ≥ 18 years Able to give written signed informed consent Investigator's assessment that the patient is able to understand, comply and follow the instructions needed to successfully participate in this trial Exclusion Criteria: Allergic to Voluven® (Fresenius Kabi AS, Halden, Norway) and contrast given during CT scan Another study interfering with current study Pregnant
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Espen Lindholm, ph.d
Organizational Affiliation
Oslo University Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Oslo University Hospital
City
Oslo
ZIP/Postal Code
0424
Country
Norway

12. IPD Sharing Statement

Plan to Share IPD
No
IPD Sharing Plan Description
No plan for individual participant data (IPD).
Citations:
PubMed Identifier
33962656
Citation
Lindholm E, Ekiz N, Tonnessen TI. Monitoring of patients with microdialysis following pancreaticoduodenectomy-the MINIMUM study: study protocol for a randomized controlled trial. Trials. 2021 May 7;22(1):329. doi: 10.1186/s13063-021-05221-9.
Results Reference
derived

Learn more about this trial

Monitoring of patIents With Microdialysis Following Pancreaticoduodenectomy

We'll reach out to this number within 24 hrs